Add Company
Join Now

Mursla Revenue and Competitors

License our Company Data API

Cambridge,

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Mursla's estimated annual revenue is currently $2.8M per year.(i)
  • Mursla's estimated revenue per employee is $155,000

Employee Data

  • Mursla has 18 Employees.(i)
  • Mursla grew their employee count by 13% last year.

Mursla's People

NameTitleEmail/Phone
1
Founder & CEOReveal Email/Phone
2
ScientistReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$99.4M45840%N/AN/A
#2
$20.6M13322%N/AN/A
#3
$156.1M146-70%$145MN/A
#4
$3.5M45-25%$150MN/A
#5
$1.6M210%$459.5MN/A
#6
$67.3M31016%$180.7MN/A
#7
$8.5M55-2%N/AN/A
#8
$256.3M10259%$168.5MN/A
#9
$2.8M18-33%N/AN/A
#10
$9.1M59-9%N/AN/A
Add Company

What Is Mursla?

Mursla is Cambridge-based startup developing a novel tech platform to trace tumours early in the blood via the discovery and quantification of cancer-specific exosome subpopulations.

keywords:N/A

N/A

Total Funding

18

Number of Employees

$2.8M

Revenue (est)

13%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Mursla News

2022-04-13 - Mursla’s nanochip technology for exosome detection poised to transform disease diagnosis

Pierre Arsène, founder and CEO of Mursla, said: “We believe that properly analysing exosome biology in patients leads to breakthrough diagnostic...

2022-04-06 - Mursla Unveils Novel Bead-Nanochip Technology for ...

This technology is part of Mursla's ExoPheno™ platform. “We believe that properly analysing exosome biology in patients leads to breakthrough...

2022-03-22 - Mursla gains mentorship support from Roche Diagnostics Ltd ...

Mursla gains mentorship support from Roche Diagnostics Ltd for pilot study in cirrhotic and liver cancer patients. 30-03-2022. Access to Roche Diagnostics'...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$3.5M18-40%N/A
#2
$2.7M18N/AN/A
#3
$1.6M18N/AN/A
#4
$1.6M186%N/A
#5
$7.5M18-14%N/A